Yetao Xu

Yetao Xu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Molecular Therapy
Verified
Journal Article
Open access
YXYetao Xu
Yetao Xu
DWDan Wu
Dan Wu
BHBingqing Hui
Bingqing Hui
LSLijun Shu
Lijun Shu
YXYetao Xu
Yetao Xu
LSLizhou Sun
Lizhou Sun
Preeclampsia (PE) is associated with maternal and fetal perinatal morbidity and mortality, which brings tremendous suffering and imposes an economic burden worldwide. The failure of uterine spiral artery remodeling may be related to the abnormal function of trophoblasts and lead to the occurrence and progression of PE. Aberrant expression of long non-coding RNAs (lncRNAs) is involved in the failure of uterine spiral artery remodeling. However, the regulation of lncRNA expression in PE is poorly characterized. Here, we reported that hypoxia-induced microRNA (miR)-218 inhibited the expression of lncRNA TUG1 by targeting FOXP1. Further RNA sequencing and mechanism analysis revealed that silencing of TUG1 increased the expression of DNA demethylase TET3 and proliferation-related DUSP family, including DUSP2, DUSP4, and DUSP5, via binding to SUV39H1 in the nucleus. Moreover, TUG1 modulated the DUSP family in vitro through a TET3-mediated epigenetic mechanism. Taken together, our results unmask a new regulatory network mediated by TUG1 as an essential determinant of the pathogenesis of PE, which regulates cell growth and possibly the occurrence and development of other diseases.

6 February 2024 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
YLYi Liu
Yi Liu
YZYuanyuan Zhang
Yuanyuan Zhang
JWJue Wang
Jue Wang
SSShengnan Song
Shengnan Song
HWHuiyan Wang
Huiyan Wang
LSLizhou Sun
Lizhou Sun
Background: Genetic disorders ascribe to half of cases of congenital hearing loss. Hearing screening is significant in detecting hearing loss (HL) but weak at diagnosis, which can be complemented by genetic screening.Methods: To find a feasible method to accomplish genetic screening and evaluate its advantage when combined with hearing screening, between 1 January 2022, and 10 December 2023, we performed an observational cohort study based on 2488 neonates from the Han population at three hospitals in Jiangsu province. Genetic screening for 20 variants in four common HL‐associated genes by multicolor melting curve analysis (MMCA) and hearing screening were offered concurrently to all participants.Results: In total, 170 (6.8%) of 2488 eligible neonates were detected at least one variant and among them, the proportion of referral was higher (p < 0.05). Genetic screening combined with hearing screening was associated with a 25.0% increase (2 of 8) in discovering cases of diagnosed hearing loss that were missed by hearing screening.Conclusion: This study suggests that genetic screening combined with hearing screening by MMCA is effective at finding potential HL cases and practical to be validated in other places.

29 January 2024 in Reproductive Biology
Verified
Journal Article
Closed access
LJLingling Jiang
Lingling Jiang
YZYuanyuan Zhu
Yuanyuan Zhu
LWLiuxin Wu
Liuxin Wu
CWCong Wang
Cong Wang
NYNana Yang
Nana Yang
LSLizhou Sun
Lizhou Sun

15 January 2026 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Open access
WCWenmei Chen
Wenmei Chen
YXYetao Xu
Yetao Xu
LSLizhou Sun
Lizhou Sun
DWDan Wu
Dan Wu
YZYuanyuan Zhang
Yuanyuan Zhang
To investigate maternal and neonatal outcomes and influencing factors in pregnant women with borderline hypertension. This prospective cohort study consecutively enrolled 600 pregnant women receiving prenatal care at two hospitals between January 1 and December 31, 2024. Participants were divided into a normotensive control group (n = 300) and a borderline hypertension group (systolic 130-139 mmHg and/or diastolic 80-89 mmHg, n = 300). The primary outcome was progression to hypertensive disorders of pregnancy (HDP). Maternal and neonatal outcomes were compared, and influencing factors were analyzed. Women with borderline hypertension exhibited significantly higher rates of cesarean delivery (63.0% vs. 42.0%; p < 0.001), HDP progression (27.0% vs. 0.0%; p < 0.001), fetal growth restriction (15.7% vs. 2.7%; p < 0.001), and NICU admission (13.7% vs. 4.0%; p < 0.001) compared to normotensive controls. Notably, later gestational age at onset of borderline hypertension was identified as a protective factor against HDP progression (OR = 0.785 per week; 95% CI: 0.724-0.851; p < 0.001), corresponding to a 21.5% risk reduction for each delayed week of onset. Borderline hypertension is associated with markedly increased adverse perinatal outcomes. Early detection and intervention-especially for women developing borderline elevation before 20 weeks-may help mitigate HDP progression. Integrating blood pressure trajectory monitoring into routine prenatal care is recommended.

23 May 2025 in Placenta
Verified
Journal Article
Closed access
XDXiaokang Deng
Xiaokang Deng
QZQing Zuo
Qing Zuo
YLYi Liu
Yi Liu
MLMeilikang Li
Meilikang Li
LWLiuxin Wu
Liuxin Wu
YXYetao Xu
Yetao Xu

8 June 2026 in iScience
Verified
Journal Article
Open access
XDXiaokang Deng
Xiaokang Deng
YLYi Liu
Yi Liu
MLMeilikang Li
Meilikang Li
WTWeichun Tang
Weichun Tang
LJLingling Jiang
Lingling Jiang
YXYetao Xu
Yetao Xu
Extra villous trophoblasts (EVTs) dysfunction impairing spiral artery remodeling (SAR) is a key preeclampsia (PE) factor. ScRNA-seq and bioinformatics analyses of preeclamptic placentas revealed the upregulation of TET3, a newly recognized regulator of epigenetic reprogramming. Untargeted metabolomics further associated TET3 with the trophoblast glucose metabolism. In vitro functional and metabolic assays demonstrated that elevated TET3 levels inhibited EVT proliferation and migration by dysregulating the mitochondrial glucose metabolism. Through integrated ScRNA-seq, microarray analysis, metabolic profiling, and chromatin immunoprecipitation assays, we found that in human trophoblasts, TET3 suppressed the expression of PDK4 by upregulating the transcription factor FOS. Mechanistically, TET3 bound to the FOS promoter and induced DNA demethylation, chromatin remodeling, and transcriptional activation. As a downstream effector, FOS bound directly to the PDK4 promoter and repressed its expression. This regulatory axis was validated in various animal models and in clinical placental specimens. Collectively, our study established that the TET3/FOS/PDK4 pathway is a critical driver of PE pathogenesis, thus offering a novel therapeutic target for PE.